SIRS Therapeutics: F4 Pharma’s FX06 shows promising results in critically ill COVID-19 patients1. July 2020|In Portfolio News|By eazee-designstudioMChE / F4 Pharma and SIRS therapeutics announce promising results from treatment of six severely ill COVID-19 patients with FX06 under “named patient use”. By time of start of FX06 administration, all patients were treated in the ICU with mechanical ventilation, and five – in addition – received extracorporeal membrane oxygenation (ECMO). Within a few days following the FX06 treatment, all patients showed an improvement of lung function parameters and a significant reduction of inflammation markers. PrevNext
